Cannabix Technologies Receives Notice of Allowance for Detection of Molecules – FAIMS U.S. Patent
UF startup Cannabix Technologies Inc., developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application No. 17/019728 entitled, “Apparatus and Methods for Detection of Molecules”.
Rafael Guzmán, SATLANTIS’ CTO, Featured on The Space Industry Podcast
Rafael Guzmán, founder and CTO of UF startup and UF Innovate | The Hub resident SATLANTIS, a Spanish business that develops Earth Observation (EO) optical payloads for small satellites around the world, is featured on The Space Industry podcast by Sat Search.
CROs dMed and Clinipace Merge To Accelerate Customer Success
dMed Global, a full-service Clinical Contract Research Organization (CRO) based in Shanghai, China, and UF startup Clinipace Incorporated, a full-service clinical CRO with headquarters in North Carolina, USA, announced that the two companies will merge.
Cannabix Technologies Develops Version 3.0 of THC Breath Analyzer Device
UF startup Cannabix Technologies Inc., developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, has developed the latest version of the THC Breath Analyzer (THCBA) prototype and portable system for field use.
New OxThera/Oxabact US Patent Granted
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.
Plasma Oxalate and Kidney Function Are Correlated in Patients With Primary Hyperoxaluria With Maintained Kidney Function – Data From Three Placebo-Controlled Studies Published
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.
UF Startup Shadow Health Is Going Big and Staying Home
In early December, local UF startup Shadow Health, which develops virtual simulations for nursing and healthcare education, became part of Elsevier, a global leader in information and analytics, that is part of RELX, an even larger global provider of information-based analytics. The acquisition will hasten Shadow Health’s ability to reach its biggest goals.
Algernon Pharmaceuticals Lead Drug Ifenprodil Named As Potential COVID-19 Treatment in European Scientific Journal
Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, said that its lead drug candidate Ifenprodil was highlighted in a European scientific journal as a potential COVID-19 treatment. In the January 5th edition of the European Archives of Psychiatry and Clinical Neuroscience, the authors of an independent research review identified Ifenprodil as a possible […]